Perdagangan Spero Therapeutics, Inc. - SPRO CFD
Tambah ke favorit- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
Spread | - | ||||||||
Biaya inap posisi Long
Long position overnight fee
Kunjungi platform | -0.024068% | ||||||||
Biaya inap posisi short
Short position overnight fee
Kunjungi platform | 0.001846% | ||||||||
Waktu biaya inap | 21:00 (UTC) | ||||||||
Kuantitas min. yang diperdagangkan | 1 | ||||||||
Mata uang | USD | ||||||||
Margin | 20% | ||||||||
Bursa efek | United States of America | ||||||||
Komisi perdagangan | 0% |
*Information provided by Capital.com
Key Stats
Prev. Close* | N/A |
Open* | N/A |
1-Year Change* | N/A |
Day's Range* | N/A |
52 wk Range | 0.68-9.00 |
Average Volume (10 days) | 646.65K |
Average Volume (3 months) | 9.28M |
Market Cap | 72.49M |
P/E Ratio | -100.00K |
Shares Outstanding | 51.78M |
Revenue | 8.81M |
EPS | -3.11 |
Dividend (Yield %) | N/A |
Beta | 0.88 |
Next Earnings Date | Mar 30, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|
Spero Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total revenue | 18.256 | 9.33 | 18.147 | 3.966 | 1.979 |
Revenue | 18.256 | 9.33 | 18.147 | 3.966 | 1.979 |
Total Operating Expense | 106.227 | 88.443 | 81.363 | 46.772 | 43.709 |
Selling/General/Admin. Expenses, Total | 41.701 | 21.44 | 15.588 | 12.887 | 10.84 |
Research & Development | 64.526 | 67.003 | 65.775 | 33.885 | 32.869 |
Operating Income | -87.971 | -79.113 | -63.216 | -42.806 | -41.73 |
Interest Income (Expense), Net Non-Operating | -1.39 | 0.401 | 1.551 | 0 | 1.541 |
Other, Net | -0.395 | 0.432 | 0.74 | 1.144 | 0.303 |
Net Income Before Taxes | -89.756 | -78.28 | -60.925 | -41.662 | -39.886 |
Net Income After Taxes | -89.756 | -78.28 | -60.925 | -41.662 | -39.886 |
Minority Interest | 0 | 1.143 | |||
Net Income Before Extra. Items | -89.756 | -78.28 | -60.925 | -41.662 | -38.743 |
Net Income | -89.756 | -78.28 | -60.925 | -41.662 | -38.743 |
Total Adjustments to Net Income | 0 | -0.549 | 0 | -7.354 | |
Income Available to Common Excl. Extra. Items | -89.756 | -78.829 | -60.925 | -41.662 | -46.097 |
Income Available to Common Incl. Extra. Items | -89.756 | -78.829 | -60.925 | -41.662 | -46.097 |
Dilution Adjustment | |||||
Diluted Net Income | -89.756 | -78.829 | -60.925 | -41.662 | -46.097 |
Diluted Weighted Average Shares | 30.8958 | 22.3861 | 18.1605 | 16.0018 | 14.3692 |
Diluted EPS Excluding Extraordinary Items | -2.90512 | -3.52133 | -3.3548 | -2.60358 | -3.20805 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | -2.90512 | -3.52133 | -3.3548 | -2.60358 | -3.20805 |
Total Extraordinary Items | 0 | 0 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total revenue | 2.069 | 2.744 | 3.064 | 5.148 | 7.3 |
Revenue | 2.069 | 2.744 | 3.064 | 5.148 | 7.3 |
Total Operating Expense | 32.276 | 30.246 | 25.588 | 23.69 | 26.703 |
Selling/General/Admin. Expenses, Total | 15.305 | 13.021 | 11.152 | 9.229 | 8.299 |
Research & Development | 16.971 | 17.225 | 14.436 | 14.461 | 18.404 |
Operating Income | -30.207 | -27.502 | -22.524 | -18.542 | -19.403 |
Interest Income (Expense), Net Non-Operating | -2.609 | -1.66 | 0.09 | 0.082 | 0.098 |
Other, Net | -0.013 | -0.078 | -0.087 | -0.112 | -0.118 |
Net Income Before Taxes | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
Net Income After Taxes | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
Net Income Before Extra. Items | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
Net Income | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
Income Available to Common Excl. Extra. Items | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
Income Available to Common Incl. Extra. Items | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
Diluted Net Income | -32.829 | -29.24 | -22.521 | -18.572 | -19.423 |
Diluted Weighted Average Shares | 32.6067 | 32.3311 | 32.1325 | 29.6754 | 29.4142 |
Diluted EPS Excluding Extraordinary Items | -1.00682 | -0.90439 | -0.70088 | -0.62584 | -0.66033 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -1.00682 | -0.90439 | -0.70088 | -0.62584 | -0.66033 |
Total Adjustments to Net Income | 0 | 0 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 157.872 | 139.145 | 95.414 | 124.219 | 92.059 |
Cash and Short Term Investments | 146.402 | 126.906 | 82.045 | 115.443 | 87.288 |
Cash & Equivalents | 112.584 | 85.209 | 29.73 | 34.08 | 87.288 |
Total Receivables, Net | 2.641 | 6.176 | 8.546 | 1.298 | 2.943 |
Prepaid Expenses | 8.829 | 6.063 | 4.823 | 7.478 | 1.828 |
Total Assets | 171.072 | 153.451 | 106.103 | 129.006 | 93.479 |
Property/Plant/Equipment, Total - Net | 7.556 | 8.783 | 7.148 | 2.893 | 1.164 |
Property/Plant/Equipment, Total - Gross | 10.436 | 11.059 | 8.663 | 3.72 | 1.807 |
Accumulated Depreciation, Total | -2.88 | -2.276 | -1.515 | -0.827 | -0.643 |
Note Receivable - Long Term | 0 | 0.311 | 0.021 | 0.233 | 0 |
Other Long Term Assets, Total | 5.644 | 5.212 | 3.52 | 1.661 | 0.256 |
Total Current Liabilities | 18.67 | 14.343 | 26.663 | 12.318 | 8.157 |
Accounts Payable | 1.101 | 1.155 | 4.147 | 3.603 | 3.47 |
Accrued Expenses | 15.712 | 13.188 | 22.516 | 8.263 | 4.321 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 1.857 | 0 | 0.452 | 0.366 | |
Total Liabilities | 82.783 | 21.411 | 31.529 | 13.506 | 8.877 |
Total Long Term Debt | 48.414 | 0 | 0 | 0 | 0 |
Minority Interest | 0.355 | 0.355 | |||
Other Liabilities, Total | 15.699 | 7.068 | 4.866 | 0.833 | 0.365 |
Total Equity | 88.289 | 132.04 | 74.574 | 115.5 | 84.602 |
Redeemable Preferred Stock | 0 | 0 | |||
Common Stock | 0.032 | 0.029 | 0.019 | 0.017 | 0.014 |
Additional Paid-In Capital | 455.719 | 409.722 | 273.966 | 254.013 | 181.428 |
Retained Earnings (Accumulated Deficit) | -367.463 | -277.707 | -199.427 | -138.502 | -96.84 |
Total Liabilities & Shareholders’ Equity | 171.072 | 153.451 | 106.103 | 129.006 | 93.479 |
Total Common Shares Outstanding | 32.3937 | 29.2603 | 19.1907 | 17.206 | 14.3692 |
Short Term Investments | 33.818 | 41.697 | 52.315 | 81.363 | |
Other Equity, Total | -0.002 | -0.007 | 0.016 | -0.028 | |
Preferred Stock - Non Redeemable, Net | 0.003 | 0.003 | |||
Total Preferred Shares Outstanding | 3.21815 | 3.21829 | |||
Long Term Debt | 48.414 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 132.704 | 157.872 | 131.769 | 106.316 | 129.492 |
Cash and Short Term Investments | 121.966 | 146.402 | 123.417 | 99.218 | 115.676 |
Cash & Equivalents | 72.111 | 112.584 | 112.859 | 71.562 | 77.042 |
Short Term Investments | 49.855 | 33.818 | 10.558 | 27.656 | 38.634 |
Total Receivables, Net | 1.991 | 2.641 | 2.584 | 2.197 | 8.622 |
Prepaid Expenses | 8.747 | 8.829 | 5.768 | 4.901 | 5.194 |
Total Assets | 145.83 | 171.072 | 144.691 | 119.594 | 143.44 |
Property/Plant/Equipment, Total - Net | 7.197 | 7.556 | 7.71 | 8.067 | 8.425 |
Note Receivable - Long Term | 0 | 0 | 0 | 0.311 | |
Other Long Term Assets, Total | 5.929 | 5.644 | 5.212 | 5.211 | 5.212 |
Total Current Liabilities | 69.199 | 18.67 | 17.258 | 12.826 | 17.763 |
Accounts Payable | 4.78 | 1.101 | 3.161 | 1.632 | 3.825 |
Accrued Expenses | 10.429 | 15.712 | 12.398 | 10.015 | 13.938 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 83.357 | 82.783 | 32.796 | 29.342 | 24.594 |
Total Long Term Debt | 0 | 48.414 | 0 | 0 | 0 |
Other Liabilities, Total | 14.158 | 15.699 | 15.538 | 16.516 | 6.831 |
Total Equity | 62.473 | 88.289 | 111.895 | 90.252 | 118.846 |
Preferred Stock - Non Redeemable, Net | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
Common Stock | 0.033 | 0.032 | 0.032 | 0.03 | 0.03 |
Additional Paid-In Capital | 462.735 | 455.719 | 450.085 | 405.923 | 415.946 |
Retained Earnings (Accumulated Deficit) | -400.292 | -367.463 | -338.223 | -315.702 | -297.13 |
Other Equity, Total | -0.006 | -0.002 | -0.002 | -0.002 | -0.003 |
Total Liabilities & Shareholders’ Equity | 145.83 | 171.072 | 144.691 | 119.594 | 143.44 |
Total Common Shares Outstanding | 32.7556 | 32.3937 | 32.2203 | 29.6992 | 29.6639 |
Total Preferred Shares Outstanding | 3.21815 | 3.21815 | 3.21815 | 3.21815 | 3.21815 |
Other Current Liabilities, Total | 53.99 | 1.857 | 1.699 | 1.179 | |
Long Term Debt | 0 | 48.414 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | -89.756 | -78.28 | -60.925 | -41.662 | -39.886 |
Cash From Operating Activities | -64.347 | -85.872 | -50.02 | -39.625 | -39.111 |
Cash From Operating Activities | 0.646 | 0.761 | 0.75 | 0.409 | 0.363 |
Non-Cash Items | 11.901 | 5.111 | 3.376 | 2.699 | -0.031 |
Changes in Working Capital | 12.862 | -13.464 | 6.779 | -1.071 | 0.443 |
Cash From Investing Activities | 7.672 | 10.47 | 29.53 | -83.156 | -0.027 |
Capital Expenditures | -0.157 | -0.314 | -2.436 | -0.027 | |
Cash From Financing Activities | 84.05 | 130.881 | 16.14 | 69.523 | 116.111 |
Financing Cash Flow Items | 47.232 | -0.953 | -0.158 | -1.312 | -4.749 |
Issuance (Retirement) of Stock, Net | 36.818 | 131.834 | 16.298 | 70.835 | 120.86 |
Net Change in Cash | 27.375 | 55.479 | -4.35 | -53.258 | 76.973 |
Other Investing Cash Flow Items, Total | 7.672 | 10.627 | 29.844 | -80.72 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -32.829 | -89.756 | -60.516 | -37.995 | -19.423 |
Cash From Operating Activities | -28.223 | -64.347 | -36.998 | -32.046 | -15.479 |
Cash From Operating Activities | 0.189 | 0.646 | 0.455 | 0.307 | 0.159 |
Non-Cash Items | 6.117 | 11.901 | 7.327 | 4.708 | 2.253 |
Changes in Working Capital | -1.7 | 12.862 | 15.736 | 0.934 | 1.532 |
Cash From Investing Activities | -16.064 | 7.672 | 30.947 | 13.922 | 3.003 |
Other Investing Cash Flow Items, Total | -16.064 | 7.672 | 30.947 | 13.922 | 3.003 |
Cash From Financing Activities | 3.814 | 84.05 | 33.701 | 4.477 | 4.309 |
Financing Cash Flow Items | 0 | 47.232 | -0.411 | -0.146 | -0.037 |
Issuance (Retirement) of Stock, Net | 3.814 | 36.818 | 34.112 | 4.623 | 4.346 |
Net Change in Cash | -40.473 | 27.375 | 27.65 | -13.647 | -8.167 |
Capital Expenditures | 0 | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
GSK plc | Corporation | 17.7507 | 9190606 | 7450000 | 2022-11-14 | MED |
Anson Funds Management LP. | Hedge Fund | 5.8321 | 3019608 | 1545736 | 2022-12-31 | HIGH |
Atlas Venture | Venture Capital | 4.651 | 2408128 | 0 | 2022-12-31 | LOW |
Pfizer Inc | Corporation | 4.5626 | 2362348 | 0 | 2022-07-20 | MED |
AWM Investment Company, Inc. | Investment Advisor/Hedge Fund | 2.5116 | 1300400 | -1000000 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.0364 | 1054388 | 665 | 2022-12-31 | LOW |
Alphabet, Inc. | Venture Capital | 1.7189 | 889979 | 0 | 2022-12-31 | LOW |
Millennium Management LLC | Hedge Fund | 1.6927 | 876398 | 188002 | 2022-12-31 | HIGH |
Murchinson Ltd. | Investment Advisor/Hedge Fund | 1.4731 | 762700 | 0 | 2022-12-31 | HIGH |
Rock Springs Capital Management LP | Hedge Fund | 1.2931 | 669533 | -101177 | 2022-12-31 | LOW |
Mahadevia (Ankit) | Individual Investor | 1.1307 | 585445 | 519628 | 2023-02-03 | MED |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.9252 | 479031 | -187473 | 2022-12-31 | LOW |
Hamed (Kamal) | Individual Investor | 0.9193 | 475957 | 265957 | 2023-02-01 | MED |
Novo Holdings A/S | Venture Capital | 0.9056 | 468902 | 0 | 2022-12-31 | LOW |
XTX Markets LLC | Investment Advisor | 0.6697 | 346734 | 346734 | 2022-12-31 | HIGH |
Renaissance Technologies LLC | Hedge Fund | 0.6623 | 342900 | 128200 | 2022-12-31 | HIGH |
Keutzer (Timothy) | Individual Investor | 0.6318 | 327144 | 262563 | 2023-02-02 | LOW |
Joseph (Tamara) | Individual Investor | 0.627 | 324644 | 262563 | 2023-02-02 | LOW |
Oasis Management Company Ltd. | Investment Advisor/Hedge Fund | 0.5562 | 288000 | 0 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.4969 | 257284 | -32974 | 2022-12-31 | LOW |
Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.
Capital.com Group500K+
Trader
92K+
Klien aktif per bulan
$53M+
Volume investasi per bulan
$30M+
Penarikan tiap bulan
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Industry: | Bio Therapeutic Drugs |
675 Massachusetts Ave Ste 14
CAMBRIDGE
MASSACHUSETTS 02139-3309
US
Income Statement
- Annual
- Quarterly
People also watch
Masih mencari broker yang bisa Anda percayai?
Bergabung dengan 500.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com